OncoMatch/Clinical Trials/NCT01891318
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Is NCT01891318 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for tumors metastatic to brain.
This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: whole brain radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center · Cleveland, Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify